Myriad Genetics, Inc.
(NASDAQ : MYGN)

( )
MYGN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 2.48%148.380.0%$1836.76m
NVAXNovavax, Inc. -7.69%221.5092.9%$1384.95m
OCGNOcugen, Inc. -10.41%8.000.0%$863.06m
AMGNAmgen, Inc. -1.07%227.521.3%$600.44m
ILMNIllumina, Inc. -3.30%445.863.5%$554.99m
REGNRegeneron Pharmaceuticals, Inc. -1.18%453.192.7%$531.63m
VRTXVertex Pharmaceuticals, Inc. -1.87%212.981.9%$510.83m
GILDGilead Sciences, Inc. -1.44%62.791.0%$494.89m
BNGOBioNano Genomics, Inc. -10.46%10.020.0%$406.61m
ALXNAlexion Pharmaceuticals, Inc. -0.54%153.652.0%$384.96m
BIIBBiogen, Inc. -1.94%277.261.7%$380.46m
CRSPCRISPR Therapeutics AG -4.67%127.280.6%$301.95m
EXASEXACT Sciences Corp. -2.61%131.3018.4%$246.20m
SRNESorrento Therapeutics, Inc. -7.75%10.121.3%$239.74m
VXRTVaxart, Inc. 2.18%7.500.0%$224.09m

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.